Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
74.15(c) 73.75(c) 73.85(c) 73.75(c) 74.5 Last
4 605 585 7 286 873 3 664 790 4 354 542 5 543 456 Volume
+1.02% -0.54% +0.14% -0.14% +1.02% Change
More quotes
Financials ($)
Sales 2017 48 454 M
EBIT 2017 11 231 M
Net income 2017 7 497 M
Debt 2017 15 114 M
Yield 2017 3,81%
Sales 2018 50 432 M
EBIT 2018 12 358 M
Net income 2018 8 589 M
Debt 2018 13 106 M
Yield 2018 4,01%
P/E ratio 2017 22,56
P/E ratio 2018 19,94
EV / Sales2017 4,37x
EV / Sales2018 4,16x
Capitalization 196 620 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
04/25Earnings Release
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
03/29 NOVARTIS : announces first CAR-T cell therapy BLA for pediatric and young adult ..
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/28 NOVARTIS : The New Americares-Sandoz Partnership Provides Even More Access to Me..
03/27 NOVARTIS AG : Blog Coverage Novartis Licences its Immunosenescence Drugs to Pure..
03/27 NOVARTIS : appoints new UK managing director
03/26 NOVARTIS INDIA : Quarterly results - novartis india limited
03/24 NOVARTIS : Global Haloperidol Market 2017 - Sandoz, Mylan, Teva, Fresenius Kabi
03/24 NOVARTIS : $11,970 Federal Contract Awarded to Alcon Laboratories
03/24 PURETECH HEALTH : Inks Deal With Novartis To Develop Ageing Disorder Therapies
03/23 NOVARTIS : Lupin receives FDA approval for generic TOBI inhalation solution
More news
Sector news : Pharmaceuticals - NEC
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS AG 
2016A trend reversal can be anticipated
More Strategies
Latest Tweets
12:40aRoche's much-anticipated MS game-changer, Ocrevus, nabs its FDA green light  
03/29FDA accepts Novartis' BLA for CAR-T candidate CTL019 under accelerated review..
1
03/29Novartis gets a speedy review for its CAR-T pioneer as FDA lines up a marketi..
4
03/29QFES Deputy Commissioner Mark Roche is live on Cyclone Debbie aftermath #sun7
4
03/29Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen  
More tweets
Qtime:239
News from SeekingAlpha
03/29 FDA accepts Novartis' BLA for CAR-T candidate CTL019 under accelerated review
03/28 NOVARTIS : The Worst Is Still Ahead
03/27 My Favorite Biotech Takeover Play
03/27 BIOLINERX : Expands Cancer Pipeline Significantly By Acquiring Novel Drug Candid..
03/24 FDA Decision For Dupixent As Novartis Drives Its CAR-T
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 80,1 $
Spread / Average Target 7,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-0.34%196 620
JOHNSON & JOHNSON9.19%340 651
ROCHE HOLDING LTD.8.73%221 256
PFIZER INC.5.17%203 427
MERCK & CO., INC.7.59%173 904
SANOFI9.15%117 271
More Results